|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386.
2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Zhang J, Raju GS, Chang DW, Lin S-H, Chen
Z and Wu X: Global and targeted circulating microRNA profiling of
colorectal adenoma and colorectal cancer. Cancer. 124:785–796.
2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Rawla P, Sunkara T and Barsouk A:
Epidemiology of colorectal cancer: Incidence, mortality, survival,
and risk factors. Prz Gastroenterol. 14:89–103. 2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
International Agency for Research on
Cancer: Estimated crude incidence and mortality rates in 2020,
worldwide, both sexes, all ages. IARC, Lyon, 2020.
|
|
5
|
Sung JJY, Ng SC, Chan FKL, Chiu HM, Kim
HS, Matsuda T, Ng SS, Lau JY, Zheng S, Adler S, et al: Asia Pacific
Working Group: An updated Asia Pacific Consensus Recommendations on
colorectal cancer screening. Gut. 64:121–132. 2015.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Shamseddine A: Cancer trends in Lebanon
and projections to 2020. Human & Health, 2015. https://www.syndicateofhospitals.org.lb/Content/uploads/SyndicateMagazinePdfs/8217_8-11.pdf.
|
|
7
|
Nagy ZB, Wichmann B, Kalmár A, Galamb O,
Barták BK, Spisák S, Tulassay Z and Molnár B: Colorectal adenoma
and carcinoma specific miRNA profiles in biopsy and their
expression in plasma specimens. Clin Epigenetics.
9(22)2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
American Cancer Society: Colorectal Cancer
Facts and Figures 2020-2022. American Cancer Society, Atlanta, GA,
2020.
|
|
9
|
Cole SR, Tucker GR, Osborne JM, Byrne SE,
Bampton PA, Fraser RJ and Young GP: Shift to earlier stage at
diagnosis as a consequence of the National Bowel Cancer Screening
Program. Med J Aust. 198:327–330. 2013.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Ni Y, Xie G and Jia W: Metabonomics of
human colorectal cancer: New approaches for early diagnosis and
biomarker discovery. J Proteome Res. 13:3857–3870. 2014.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Knudsen AB, Zauber AG, Rutter CM, Naber
SK, Doria-Rose VP, Pabiniak C, Johanson C, Fischer SE,
Lansdorp-Vogelaar I and Kuntz KM: Estimation of benefits, burden,
and harms of colorectal cancer screening strategies: Modeling Study
for the US Preventive Services Task Force. JAMA. 315:2595–2609.
2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Gellad ZF, Stechuchak KM, Fisher DA, Olsen
MK, McDuffie JR, Østbye T and Yancy WS: Am J. Gastroenterol.
106:1125–1134. 2011.
|
|
13
|
Brînzan C, Aşchie M, Cozaru G, Dumitru E
and Mitroi A: The diagnostic value of miR-92a, -143, and -145
expression levels in patients with colorectal adenocarcinoma from
Romania. Medicine (Baltimore). 99(e21895)2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Al-Sheikh YA, Ghneim HK, Softa KI,
Al-Jobran AA, Al-Obeed O, Mohamed MA, Abdulla M and Aboul-Soud MA:
Expression profiling of selected microRNA signatures in plasma and
tissues of Saudi colorectal cancer patients by qPCR. Oncol Lett.
11:1406–1412. 2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Jung G, Hernández-Illán E, Moreira L,
Balaguer F and Goel A: Epigenetics of colorectal cancer: Biomarker
and therapeutic potential. Nat Rev Gastroenterol Hepatol.
17:111–130. 2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Xiao Z, Chen S, Feng S, Li Y, Zou J, Ling
H, Zeng Y and Zeng X: Function and mechanisms of microRNA-20a in
colorectal cancer. Exp Ther Med. 19:1605–1616. 2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Forterre A, Komuro H, Aminova S and Harada
M: A comprehensive review of cancer MicroRNA therapeutic delivery
strategies. Cancers (Basel). 12(1852)2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Gasparello J, Papi C, Allegretti M,
Giordani E, Carboni F, Zazza S, Pescarmona E, Romania P, Giacomini
P, Scapoli C, et al: A distinctive microRNA (miRNA) signature in
the blood of colorectal cancer (CRC) patients at surgery. Cancers
(Basel). 12(12)2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Vishnoi K, Viswakarma N, Rana A and Rana
B: Transcription factors in cancer development and therapy. Cancers
(Basel). 12(E2296)2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Schetter AJ, Okayama H and Harris CC: The
role of microRNAs in colorectal cancer. Cancer J. 18:244–252.
2012.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Meng W-J, Yang L, Ma Q, Zhang H, Adell G,
Arbman G, Wang ZQ, Li Y, Zhou ZG and Sun XF: MicroRNA expression
profile reveals miR-17-92 and miR-143-145 cluster in synchronous
colorectal cancer. Medicine (Baltimore). 94(e1297)2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Schee K, Boye K, Abrahamsen TW, Fodstad Ø
and Flatmark K: Clinical relevance of microRNA miR-21, miR-31,
miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer. BMC
Cancer. 12(505)2012.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Saberinia A, Alinezhad A, Jafari F,
Soltany S and Akhavan Sigari R: Oncogenic miRNAs and target
therapies in colorectal cancer. Clin Chim Acta. 508:77–91.
2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Eslamizadeh S, Heidari M, Agah S,
Faghihloo E, Ghazi H, Mirzaei A and Akbari A: The role of MicroRNA
signature as diagnostic biomarkers in different clinical stages of
colorectal cancer. Cell J. 20:220–230. 2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Slattery ML, Pellatt AJ, Lee FY, Herrick
JS, Samowitz WS, Stevens JR, Wolff RK and Mullany LE: Infrequently
expressed miRNAs influence survival after diagnosis with colorectal
cancer. Oncotarget. 8:83845–83859. 2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Zhu Y, Wu G, Yan W, Zhan H and Sun P:
miR-146b-5p regulates cell growth, invasion, and metabolism by
targeting PDHB in colorectal cancer. Am J Cancer Res. 7:1136–1150.
2017.PubMed/NCBI
|
|
27
|
Kanaan Z, Rai SN, Eichenberger MR, Barnes
C, Dworkin AM, Weller C, Cohen E, Roberts H, Keskey B, Petras RE,
et al: Differential microRNA expression tracks neoplastic
progression in inflammatory bowel disease-associated colorectal
cancer. Hum Mutat. 33:551–560. 2012.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Shen X, Jiang H, Chen Z, Lu B, Zhu Y, Mao
J, Chai K and Chen W: MicroRNA-145 inhibits cell migration and
invasion in colorectal cancer by targeting TWIST. OncoTargets Ther.
12:10799–10809. 2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Feng Y, Zhu J, Ou C, Deng Z, Chen M, Huang
W and Li L: MicroRNA-145 inhibits tumour growth and metastasis in
colorectal cancer by targeting fascin-1. Br J Cancer.
110:2300–2309. 2014.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Li J, Xia L, Zhou Z, Zuo Z, Xu C, Song H
and Cai J: MiR-186-5p upregulation inhibits proliferation,
metastasis and epithelial-to-mesenchymal transition of colorectal
cancer cell by targeting ZEB1. Arch Biochem Biophys. 640:53–60.
2018.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-ΔΔC(T)) Method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
|
|
32
|
To KK, Tong CW, Wu M and Cho WC: MicroRNAs
in the prognosis and therapy of colorectal cancer: From bench to
bedside. World J Gastroenterol. 24:2949–2973. 2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Lan H, Lu H, Wang X and Jin H: MicroRNAs
as potential biomarkers in cancer: Opportunities and challenges.
BioMed Res Int. 2015(125094)2015.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Hrašovec S and Glavač D: MicroRNAs as
novel biomarkers in colorectal cancer. Front Genet.
3(180)2012.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Jarry J, Schadendorf D, Greenwood C, Spatz
A and van Kempen LC: The validity of circulating microRNAs in
oncology: Five years of challenges and contradictions. Mol Oncol.
8:819–829. 2014.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Rawlings-Goss RA, Campbell MC and Tishkoff
SA: Global population-specific variation in miRNA associated with
cancer risk and clinical biomarkers. BMC Med Genomics.
7(53)2014.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Yu T, Ma P, Wu D, Shu Y and Gao W:
Functions and mechanisms of microRNA-31 in human cancers. Biomed
Pharmacother. 108:1162–1169. 2018.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Wang D, Liu Q, Ren Y, Zhang Y, Wang X and
Liu B: Association analysis of miRNA-related genetic polymorphisms
in miR-143/145 and KRAS with colorectal cancer susceptibility and
survival. Biosci Rep. 41(41)2021.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Mi B, Li Q, Li T, Liu G and Sai J: High
miR-31-5p expression promotes colon adenocarcinoma progression by
targeting TNS1. Aging (Albany NY). 12:7480–7490. 2020.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Igarashi H, Kurihara H, Mitsuhashi K, Ito
M, Okuda H, Kanno S, Naito T, Yoshii S, Takahashi H, Kusumi T, et
al: Association of MicroRNA-31-5p with clinical efficacy of
anti-EGFR therapy in patients with metastatic colorectal cancer.
Ann Surg Oncol. 22:2640–2648. 2015.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Michael MZ, O'Connor SM, van Holst
Pellekaan NG, Young GP and James RJ: Reduced accumulation of
specific microRNAs in colorectal neoplasia. Mol Cancer Res.
1:882–891. 2003.PubMed/NCBI
|
|
42
|
Toiyama Y, Takahashi M, Hur K, Nagasaka T,
Tanaka K, Inoue Y, Kusunoki M, Boland CR and Goel A: Serum miR-21
as a diagnostic and prognostic biomarker in colorectal cancer. J
Natl Cancer Inst. 105:849–859. 2013.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Slaby O, Svoboda M, Fabian P, Smerdova T,
Knoflickova D, Bednarikova M, Nenutil R and Vyzula R: Altered
expression of miR-21, miR-31, miR-143 and miR-145 is related to
clinicopathologic features of colorectal cancer. Oncology.
72:397–402. 2007.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Cui Q: Significance of miR-27a and miR-31
in early diagnosis and prognosis of colorectal cancer. Oncol Lett.
18:3092–3096. 2019.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Peng J, Xie Z, Cheng L, Zhang Y, Chen J,
Yu H, Li Z and Kang H: Paired design study by real-time PCR:
miR-378* and miR-145 are potent early diagnostic biomarkers of
human colorectal cancer. BMC Cancer. 15(158)2015.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Xiang Y, Tian Q, Guan L and Niu S-S: The
dual role of miR-186 in cancers: Oncomir battling with tumor
suppressor miRNA. Front Oncol. 10(233)2020.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Islam F, Gopalan V, Vider J, Wahab R,
Ebrahimi F, Lu CT, Kasem K and Lam AKY: MicroRNA-186-5p
overexpression modulates colon cancer growth by repressing the
expression of the FAM134B tumour inhibitor. Exp Cell Res.
357:260–270. 2017.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Geraldo MV, Fuziwara CS, Friguglieti CU,
Costa RB, Kulcsar MA, Yamashita AS and Kimura ET: MicroRNAs
miR-146-5p and let-7f as prognostic tools for aggressive papillary
thyroid carcinoma: A case report. Arq Bras Endocrinol Metabol.
56:552–557. 2012.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Patnaik SK, Kannisto E, Mallick R and
Yendamuri S: Overexpression of the lung cancer-prognostic miR-146b
microRNAs has a minimal and negative effect on the malignant
phenotype of A549 lung cancer cells. PLoS One.
6(e22379)2011.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Yoon SO, Kim EK, Lee M, Jung WY, Lee H,
Kang Y, Jang YJ, Hong SW, Choi SH and Yang WI: NOVA1 inhibition by
miR-146b-5p in the remnant tissue microenvironment defines occult
residual disease after gastric cancer removal. Oncotarget.
7:2475–2495. 2016.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Al-Khalaf HH and Aboussekhra A:
MicroRNA-141 and microRNA-146b-5p inhibit the prometastatic
mesenchymal characteristics through the RNA-binding protein AUF1
targeting the transcription factor ZEB1 and the protein kinase AKT.
J Biol Chem. 289:31433–31447. 2014.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Lin F, Wang X, Jie Z, Hong X, Li X, Wang M
and Yu Y: Inhibitory effects of miR-146b-5p on cell migration and
invasion of pancreatic cancer by targeting MMP16. J Huazhong Univ
Sci Technolog Med Sci. 31:509–514. 2011.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Hurst DR, Edmonds MD, Scott GK, Benz CC,
Vaidya KS and Welch DR: Breast cancer metastasis suppressor 1
up-regulates miR-146, which suppresses breast cancer metastasis.
Cancer Res. 69:1279–1283. 2009.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Katakowski M, Zheng X, Jiang F, Rogers T,
Szalad A and Chopp M: MiR-146b-5p suppresses EGFR expression and
reduces in vitro migration and invasion of glioma. Cancer Invest.
28:1024–1030. 2010.PubMed/NCBI View Article : Google Scholar
|
